Two Types of Autoimmune Addison's Disease Associated with Different Polyglandular Autoimmune (PGA) Syndromes

  title={Two Types of Autoimmune Addison's Disease Associated with Different Polyglandular Autoimmune (PGA) Syndromes},
  author={M Neufeld and Noel Keith Maclaren and Robert M. Blizzard},
A review of 295 patients with autoimmune Addison's disease which occurred as part of a polyglandular autoimmune syndrome is presented. Information of 41 cases was obtained from our clinics and from the examination of medical records, while 254 cases were culled from the literature. We report that autoimmune Addison's disease in association with other autoimmune diseases occurs in at least two distinct types. Addison's disease occurring in Type I polyglandular autoimmune disease (PGA) is… Expand
Late Diagnosed Type II Autoimmune Polyglandular Failure Syndrome: A Case Report
The literature was reviewed based on the case of a patient with a history of hypothyroidism and amenorrhea, who was followed for impaired consciousness, and subsequently, recommended antidepressant therapy, and was diagnosed with APS type II on further evaluation. Expand
A rare simultaneous manifestation of polyglandular autoimmune syndrome type II
An interesting case of a young male presenting with simultaneous manifestation of Addison’s disease and Graves, with coincident asymptomatic coeliac disease, as a rare manifestation of polyglandular autoimmune syndrome type II is described. Expand
Precocious presentation of autoimmune polyglandular syndrome type 2 associated with an AIRE mutation
The description of an uncommon case of type 2 APS with precocious presentation associated with an AIRE mutation in a very young girl could help to clarify the role of AIRE in the development of autoimmune diseases. Expand
Update on autoimmune polyendocrine syndromes (APS).
Criteria for defining a disease as autoimmune are presented, the classification, epidemiology, pathogenesis, genetic, animal models, clinical features, laboratory's tests, imaging, therapy, recent progresses in understanding the APS and a detailed analysis of large group of patients affected by different types of APS are proposed and discussed. Expand
Autoimmune Polyglandular Syndrome Type II: Epidemiological, Clinical and Immunological Data
The present study indicates that most patients with autoimmune thyroid disease will not develop additional endocrine disease and if they do, the time interval until the onset of a further autoimmune disease was relatively short and when thyroid disease was a second component disease a longer period of time elapsed. Expand
Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence
A comprehensive review of the studies on APS1-associated AAD from initial case reports to the most recent scientific findings. Expand
CHAPTER 38 – Polyendocrine Syndromes
The occurrence of Addison's disease, when associated with other diseases, is divided into two autoimmune polyglandular also known as polyendocrine syndromes (APS), type 1 and type 2, which is a genetically complex disease with a multifactorial etiology. Expand
Autoantigens in Addison's disease and associated syndromes
  • A. Weetman
  • Medicine
  • Clinical and experimental immunology
  • 1997
The demonstration of autoantibodies against the adrenal cortex by complement fixation and immunofluorescence was the first major step in defining the autoimmune basis for Addison’s disease, although only 50–60% of patients have adrenal antibodies by such techniques. Expand
Genetic Dissection of Autoimmune Polyendocrine Syndrome Type 2
The clinical diagnosis of APS1 is made in an individual who presents with at least two out of three cardinal symptoms, namely autoimmune Addison's disease, autoimmune hypoparathyroidism, and mucocutaneous candidiasis. Expand
The genetics of autoimmune polyendocrine syndrome type II.
Improved genetic testing combined with testing for 21-hydroxylase autoantibodies might allow the identification of relatively high-risk populations (greater than 1 in 200 defined genetic risk compared with 1 in 10,000 population risk). Expand